HCN Investigates: What Are Synthetic Cannabinoids?
About the Author: HCN News Team
Related Posts
Latest News
High Tide Inc. Reports Record Revenue and Consistent Profitability in Q3 2024
LOS ANGELES- High Tide Inc. reported strong financial results for the third fiscal quarter of 2024, with record revenue of $131.7 million, reflecting a 6% increase year-over-year and sequentially. This revenue growth underscores the company's ...
MediPharm Labs Achieves Debt-Free Status with $2.1M Repayment
LOS ANGELES- MediPharm Labs Corp., a pharmaceutical company specializing in cannabis-based health products, has announced the repayment of its remaining $2.1 million convertible debt, making the company materially debt-free. With over $13 million in cash ...
Silo Pharma Advances Regulatory Path for PTSD Treatment SPC-15
LOS ANGELES- Silo Pharma, Inc. a developmental stage biopharmaceutical company, has submitted a proposal for FDA approval of its PTSD treatment, SPC-15, through the 505(b)(2) regulatory pathway. This pathway is designed to shorten clinical timelines ...
